{"title":"核酸检测与酶联免疫吸附法检测HIV、HBV、HCB的性能分析","authors":"Wei Huang , Wei Wei , Xiao Tian Shi , Tianlun Jiang","doi":"10.1016/j.flm.2017.12.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To explore the clinical efficacy of Nucleic acid testing (NAT) in combination with Enzyme linked immunosorbent assay (ELISA).</p></div><div><h3>Methods</h3><p>Between January 2015 and December 2016, 106,488 specimens from hospitalized patients were detected for HIV, HBV, and HCV by using NAT plus ELISA to compare the positive and negative coincidence rate in the same patient.</p></div><div><h3>Results</h3><p>99.85% (106,324) HIV results, 94.80% (100,951) HBV results and 99.45% (105,902) HCV results were identical by both tests. The results, showing NAT<sup>+</sup>/ELISA<sup>−</sup>, for HIV, HBV, and HCV were 21, 316 and 0 respectively, and the results, showing NAT<sup>+</sup>/ELISA<sup>−</sup>, for HIV, HBV, and HCV were 143, 4958 and 586 respectively.</p></div><div><h3>Conclusions</h3><p>The combination of NAT and ELISA could effectively improve the detection accuracy and screening efficiency for HIV, HBV and HCV, decrease the rate of missed detection, and reduce the risk of iatrogenic infection.</p></div>","PeriodicalId":100555,"journal":{"name":"Frontiers in Laboratory Medicine","volume":"1 4","pages":"Pages 200-202"},"PeriodicalIF":0.0000,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.flm.2017.12.004","citationCount":"6","resultStr":"{\"title\":\"The analysis of the detection performance of nucleic acid testing and ELISA for HIV, HBV and HCB\",\"authors\":\"Wei Huang , Wei Wei , Xiao Tian Shi , Tianlun Jiang\",\"doi\":\"10.1016/j.flm.2017.12.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>To explore the clinical efficacy of Nucleic acid testing (NAT) in combination with Enzyme linked immunosorbent assay (ELISA).</p></div><div><h3>Methods</h3><p>Between January 2015 and December 2016, 106,488 specimens from hospitalized patients were detected for HIV, HBV, and HCV by using NAT plus ELISA to compare the positive and negative coincidence rate in the same patient.</p></div><div><h3>Results</h3><p>99.85% (106,324) HIV results, 94.80% (100,951) HBV results and 99.45% (105,902) HCV results were identical by both tests. The results, showing NAT<sup>+</sup>/ELISA<sup>−</sup>, for HIV, HBV, and HCV were 21, 316 and 0 respectively, and the results, showing NAT<sup>+</sup>/ELISA<sup>−</sup>, for HIV, HBV, and HCV were 143, 4958 and 586 respectively.</p></div><div><h3>Conclusions</h3><p>The combination of NAT and ELISA could effectively improve the detection accuracy and screening efficiency for HIV, HBV and HCV, decrease the rate of missed detection, and reduce the risk of iatrogenic infection.</p></div>\",\"PeriodicalId\":100555,\"journal\":{\"name\":\"Frontiers in Laboratory Medicine\",\"volume\":\"1 4\",\"pages\":\"Pages 200-202\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.flm.2017.12.004\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Laboratory Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2542364917301334\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Laboratory Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2542364917301334","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The analysis of the detection performance of nucleic acid testing and ELISA for HIV, HBV and HCB
Objective
To explore the clinical efficacy of Nucleic acid testing (NAT) in combination with Enzyme linked immunosorbent assay (ELISA).
Methods
Between January 2015 and December 2016, 106,488 specimens from hospitalized patients were detected for HIV, HBV, and HCV by using NAT plus ELISA to compare the positive and negative coincidence rate in the same patient.
Results
99.85% (106,324) HIV results, 94.80% (100,951) HBV results and 99.45% (105,902) HCV results were identical by both tests. The results, showing NAT+/ELISA−, for HIV, HBV, and HCV were 21, 316 and 0 respectively, and the results, showing NAT+/ELISA−, for HIV, HBV, and HCV were 143, 4958 and 586 respectively.
Conclusions
The combination of NAT and ELISA could effectively improve the detection accuracy and screening efficiency for HIV, HBV and HCV, decrease the rate of missed detection, and reduce the risk of iatrogenic infection.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
